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www.cdatm.orgAbstractObjective: Limited data are available on the direct costs of hospitalization owing to thromboembolism and bleeding in patients
with atrial fibrillation (AF) in China. Such data are essential for policy development, service planning, and cost-effectiveness
analysis of new therapeutic strategies. This study aimed to provide detailed data regarding in-hospital direct costs for these pa-
tients, compare the costs at different scenarios, and identify independent factors that may predict the costs.
Methods: We collected data regarding in-hospital direct costs among patients with AF who were hospitalized owing to
ischemic stroke (IS), transient ischemic attack (TIA), intracranial hemorrhage (ICH), or major gastrointestinal bleeding. All
data were collected from 7 representative tertiary referral hospitals and 3 secondary care hospitals from December 2009 to
October 2014.
Results: In total, 312 eligible patients with thromboembolism and 143 patients with major bleeding were identified, and their
hospital charts were reviewed. The median in-hospital direct costs were 17,857 Chinese Yuan (CNY) for IS and 16,589 CNY for
TIA (equivalent to 2907 US dollars and 2701 US dollars, respectively). For patients with major bleeding, the costs were 27,924
CNY for ICH and 18,196 CNY for major gastrointestinal bleeding (equivalent to 4546 US dollars and 2962 US dollars, respec-
tively). The direct costs were mainly driven by medications, which accounted for approximately 33.4%e36.1% in different groups
of patients. The direct costs were highly related to the hospital level and National Institutes of Health Stroke Scale scores in patients
with thromboembolism; in patients with ICH, the factors included hospital level, warfarin treatment before admission, and prior
hospitalization for stroke.
Conclusions: Given the high prevalence, AF-related thromboembolism and bleeding impose considerable economic burden on the
Chinese society. Efforts to improve the management of AF may confer substantial economic benefits.* Corresponding author.
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Atrial fibrillation (AF) is one of the most common
causes of stroke, conferring a five-times higher risk
of stroke on patients compared to the risk in the
general population.1 AF-related stroke is nearly twice
as likely to be fatal as non-AF stroke, and functional
deficits are likely to be more severe among survi-
vors.2 Several prior studies have reported that the
mean costs of ischemic stroke (IS) were significantly
higher for patients with AF than for those without
AF.3e6 Two national database studies in Europe7,8
estimated the mean costs for intracranial hemor-
rhage, gastrointestinal bleeding, and other major
bleeding events in patients with AF. The acute care
costs were 7331, 3601, 3941 Euros (EUR), and the
average 3-year societal costs were 27,627, 17,868,
and 12,384 EUR, respectively, suggesting that
bleeding events also conferred a substantial economic
burden on patients with AF.
With the wide adoption of new treatments among
patients with AF for stroke prevention, such as non-
vitamin K antagonist oral anticoagulants (NOACs)
and left atrial appendage occlusion procedures, it is
important to evaluate the costs of these new treatments
on the healthcare system and the money they will save
by providing more effective stroke prevention and
reducing the adverse events of bleeding.9,10 Hence,
accurate data on hospitalization costs related to AF-
associated stroke and bleeding are essential for
informed policies and decision making.
However, the available data on the health eco-
nomics of patients with AF-related stroke and
bleeding are scarce, especially for the healthcare
system in Asian countries such as China. This study
aimed to provide detailed data regarding in-hospital
direct costs for patients with AF who are hospital-
ized owing to acute thromboembolism and bleeding
events, compare the costs at different scenarios,
and identify independent factors that may predict
the costs.Methods
Data source
This cost-of-illness study was conducted in 7
representative tertiary hospitals and 3 secondary care
hospitals in Beijing. Tertiary hospitals were referral
hospitals providing high-level medical services to
several geographic regions. Secondary care hospitals
usually provide general medical care in the regions
where they are located. In all the participating hospi-
tals, electronic medical records and detailed medical
costs during hospitalization were available, and data
were abstracted through chart review.
Data of all patients with a diagnosis of AF and of
those hospitalized owing to new-onset stroke or tran-
sient ischemic attack (TIA) from January 2012 toMarch
2014 were collected. As major bleeding-induced hos-
pitalization was less common, we expanded the data
collection window to December 2009 to October 2014,
to increase our sample size.
Study population
Eligible patients were 18 years of age, and the
diagnoses were identified by the International Classi-
fication of Diseases, 10th Revision (ICD-10), coded by
the discharging hospital.
For patients with thromboembolism, the inclusion
criteria were as follows: (1) hospitalization owing to IS
or TIA; and (2) a history of AF or newly diagnosed AF
during the index hospitalization.
For patients with major bleeding, the inclusion
criteria were as follows: (1) hospitalization owing to
intracranial hemorrhage (ICH) or major gastrointes-
tinal bleeding (major gastrointestinal bleeding was
defined as bleeding leading to transfusion of at least
two units of whole blood or erythrocytes, requiring
hospitalization or surgery, resulting in permanent
disability); and (2) a history of AF or newly diagnosed
AF during the index hospitalization.
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criteria: (1) transient or reversible AF; (2) diagnosis of
rheumatic mitral stenosis or mitral valve prostheses; (3)
hospital discharge against physician advice or transfer
to another hospital; (4) bleeding related to tumors,
trauma, immunodeficiency, and pregnancy.
Patient consent forms were exempted as this study
was a retrospective study using data from medical re-
cords. In addition, no individualized patient data were
published or revealed. The Ethics Committee of Bei-
jing Anzhen Hospital, the Capital Medical University
approved the study protocol.
Data collection
The data abstracted from medical records included
sociodemographic characteristics, medical history, in-
formation on smoking and alcohol consumption, and
variables related to hospitalization. Medication usage
information, including that on preadmission warfarin,
antiplatelet agents, non-steroidal anti-inflammatory
drugs, and steroids, was also obtained. Stroke severity,
evaluated by the National Institutes of Health Stroke
Scale (NIHSS), was also abstracted.
In-hospital direct costs
Data on costs were collected from medical re-
cords. All costs during hospitalization were classified
into 8 categories, namely medication (administered
during hospitalization and prescribed at discharge;
usage of traditional Chinese herbs was also included),
medical treatment (such as monitoring or infusion
expenditure), laboratory testing (all blood tests or
other sample tests within laboratories, such as routine
blood testing or biochemistry tests), imaging exam
(such as MRI and CT), costs of provided healthcare
materials, nursing care, bed costs, and warming and
other add-on costs.
Considering the impact of inflation, all costs were
expressed in the year 2014 in Chinese Yuan (CNY),
with a 5% discount rate applied. A conversion of 6.14
(central parity rate in 2014) was applied to express the
costs in US Dollars.
Statistical analysis
Patient characteristics and cost data were reported
according to the diagnosis (IS, TIA, ICH or major
gastrointestinal bleeding). Patient characteristics were
summarized using descriptive statistics. Categorical var-
iables were shown as n (%), whereas continuous vari-
ables were shown as mean ± standard deviation (SD).Owing to the skewed distribution of costs and length-
of-stay (LOS) data, the medians of total direct costs,
direct costs per day, and each of the eight direct-cost
components were reported. In-hospital direct costs
were also depicted across the possible factors to
compare the costs in specific subgroups. Multiple linear
regression analysis was performed to determine the
predictors of higher hospitalization costs; all the baseline
variables were included in the analysis, and the depen-
dent variable in the regression analyses was log10
transformed. A P value < 0.05 was considered statisti-
cally significant. All analyses were conducted using SAS
software (version 9.2, SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
Overall, 312 eligible patients with thromboembo-
lism and 143 patients with bleeding were reviewed.
Baseline characteristics of the study population are
shown in Table 1. About 72.4% of patients with
thromboembolism were treated in tertiary hospitals.
The mean ages of patients with TIA and IS were 77.2
and 75.6 years, respectively. About 88% of patients
with major bleeding were treated in tertiary hospitals,
with the mean ages of patients with ICH and major
gastrointestinal bleeding being 72.6 and 73.8 years,
respectively.
In-hospital direct costs
The median in-hospital direct costs for each patient
were 17,857 CNY for IS, 16,589 CNY for TIA, 27,924
CNY for ICH, and 18,196 CNY for major gastroin-
testinal bleeding (equivalent to 2908, 2702, 4548, 2964
US Dollars, respectively) (Table 2). The highest in-
hospital costs were observed in patients with ICH.
When dividing the total direct costs by the LOS, the
direct costs per day remained the highest in patients
with ICH, followed by major gastrointestinal bleeding,
IS, and TIA. The major drivers of direct costs were
medication costs using Western drugs.
In-hospital direct costs in different subgroups
In-hospital direct costs stratified by demographic,
clinical variables, preadmission treatment, and
stroke severity are shown in Table 3. As the number
of patients with TIA was limited, the TIA and
IS groups were combined as the thromboembolism
group.
Table 2
In-hospital direct costs in CNY for all patients of thromboembolism and bleeding groups.
Variables Thromboembolism group Bleeding group
TIA (n ¼ 20) IS (n ¼ 292) ICH (n ¼ 92) Major gastrointestinal bleeding (n ¼ 51)
Length of stay, days 17 15 18 14
Direct costs per day, CNY 934 1211 1647 1435
Total direct costs, CNY 16,589 17,857 27,924 18,196
Bed, CNY(%) 444 (2.0) 390 (1.6) 538 (1.7) 432 (2.0)
Laboratory test, CNY(%) 2383 (10.9) 2113 (8.8) 2335 (7.3) 2468 (11.4)
Imaging, CNY(%) 3125 (14.3) 1794 (7.4) 2009 (6.3) 1505 (6.9)
Doctor service, CNY(%) 829 (3.8) 1043 (4.3) 3352 (10.5) 912 (4.2)
Nursing care, CNY(%) 143 (0.7) 135 (0.6) 171 (0.5) 117 (0.5)
Healthcare material, CNY(%) 1322 (6.0) 1030 (4.3) 2329 (7.3) 1754 (8.1)
Medication, CNY(%) 7423 (33.9) 8705 (36.1) 10,608 (33.4) 7256 (33.5)
Chinese drugs, CNY(%) 402 (1.8) 982 (4.1) 49 (0.2) 0
Western drugs, CNY(%) 5376 (24.5) 7577 (31.4) 10,117 (31.8) 7004 (32.3)
Others, CNY(%) 463 (2.1) 328 (1.4) 273 (0.9) 224 (1.0)
Data are presented as median or median (%). CNY: Chinese Yuan; TIA: transient ischemic attack; IS: ischemic stroke; ICH: intracranial
hemorrhage.
Table 1
Baseline characteristics of patients on admission.
Characteristics Thromboembolism Bleeding
TIA (n ¼ 20) IS
(n ¼ 292)
ICH (n ¼ 92) Major gastrointestinal
bleeding (n ¼ 51)
Age, years, mean ± SD 77.2 ± 10.2 75.6 ± 9.6 72.6 ± 10.8 73.8 ± 10.3
Female, % 70.0 48.6 35.9 35.3
Tertiary hospital, % 90.0 71.2 82.6 98.0
AF history, years, mean ± SD 5.4 ± 5.1 8.0 ± 9.9 5.9 ± 6.7 5.5 ± 5.6
AF history, years, median 4.0 4.0 3.5 3.0
NIHSS scores, mean ± SD NA 7.5 ± 8.2 NA NA
CHA2DS2-VASc, mean ± SD 4.4 ± 1.6 4.4 ± 1.7 3.3 ± 1.4 3.6 ± 1.7
HAS-BLED score, mean ± SD 2.3 ± 0.6 2.9 ± 1.1 2.6 ± 1.3 3.1 ± 1.2
Preadmission warfarin treatment, % 5.6 11.1 11.2 20.4
Preadmission antiplatelet treatment, % 40.0 33.5 23.3 40.0
INR on admission, mean ± SD 1.2 ± 0.3 1.1 ± 0.5 1.1 ± 0.3 1.3 ± 0.7
Prior hospitalization owing to stroke, % 15.0 37.8 19.5 29.4
AF type, %
Paroxysmal 35.0 22.3 29.4 37.3
Persistent 45.0 47.3 45.7 47.1
Unspecified 20.0 30.5 25.0 15.7
Comorbidities, %
Hypertension 70.0 73.9 81.5 70.6
Diabetes mellitus 50.0 32.5 25.0 43.1
Congestive heart failure 20.0 24.0 13.2 25.5
Prior bleeding 10.0 9.6 12.0 19.6
Prior thromboembolism 15.0 43.2 32.6 43.1
Vascular disease 45.0 25.4 14.1 25.0
Abnormal liver function 0 2.7 1.1 5.9
Abnormal renal function 0 2.4 3.3 11.8
Smoking, % 25.0 24.0 19.6 33.3
Excessive alcohol, % 15.0 15.5 15.2 17.7
TIA: transient ischemic attack; IS: ischemic stroke; ICH: intracranial hemorrhage; AF: atrial fibrillation; NIHSS: National Institutes of Health
Stroke Scale; INR: international normalization ratio; SD: standard deviation; HAS-BLED: Hypertension, Abnormal Renal/Liver Function, Stroke,
Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; NA: not applicable.
130 S.-S. Chang et al. / Chronic Diseases and Translational Medicine 4 (2018) 127e134
Table 3
In-hospital direct costs in different subgroups.














<65 42 15.0 15,742 20 19.0 31,667 10 14.5 17,407
65e74 71 17.0 17,944 25 17.0 26,004 16 14.5 18,739
75 199 15.0 16,608 47 20.0 22,565 25 14.0 13,986
Gender
Male 156 15.0 16,161 59 20.0 35,470 33 14.0 16,504
Female 156 15.0 17,288 33 17.0 22,224 18 14.5 16,491
AF type
Paroxysmal 72 15.0 17,420 27 20.0 31,924 19 15.0 18,311
Persistent 147 16.0 16,011 42 18.0 22,025 24 14.5 17,416
Unspecified 93 15.0 16,742 23 17.0 47,574 8 10.0 12,814
Hospital level
Secondary care hospital 86 18.0 13,201 16 19.5 15,692 1 14.0 78,748
Tertiary referral hospital 226 14.0 17,330 76 18.0 26,909 50 14.0 16,146
Stroke severity
Mild (NIHSS 1e4) 120 15.0 15,151 NA NA NA NA NA NA
Moderate (NIHSS 5e15) 76 15.0 19,487 NA NA NA NA NA NA
Moderately severe (NIHSS 16e20) 25 21.0 31,298 NA NA NA NA NA NA
Severe (NIHSS 21e42) 25 18.0 39,272 NA NA NA NA NA NA
Preadmission warfarin treatment
No 264 15.5 16,854 79 18.0 26,115 39 14.0 15,788
Yes 32 15.0 14,719 10 13.5 22,395 10 14.0 15,816
Preadmission antiplatelet treatment
No 205 15.0 15,883 69 20.0 24,649 30 15.0 16,491
Yes 105 16.0 17,607 21 17.0 26,004 20 12.0 17,058
History of hospitalization owing to stroke
Twice 113 16.0 19,036 14 17.0 46,377 15 15.0 19,199
First time 198 15.0 15,465 77 18.0 24,552 36 14.0 14,887
Chronic heart failure
No 228 15.0 16,836 79 18.0 26,004 38 14.5 16,146
Yes 74 15.0 17,034 12 16.0 22,818 13 12.0 18,327
Hypertension
No 81 14.0 14,741 17 23.0 40,111 15 14.0 15,788
Yes 229 16.0 17,186 75 17.0 22,224 36 14.0 18,422
Diabetes mellitus
No 205 15.0 17,285 69 18.0 31,924 29 13.0 13,809
Yes 105 16.0 16,047 23 17.0 18,417 22 15.0 18,986
Prior thromboembolism
No 182 15.0 15,246 62 19.5 26,059 29 14.0 13,986
Yes 129 16.0 18,897 30 16.0 23,607 22 15.0 18,905
Vascular disease
No 225 15.0 16,608 79 20.0 31,924 36 15.0 15,245
Yes 82 16.5 17,657 13 13.0 16,778 12 12.0 18,986
Prior bleeding
No 169 15.0 16,608 38 16.0 23,222 22 14.0 13,415
Yes 30 17.5 23,820 11 17.0 13,201 10 14.0 16,593
LOS: length of stay; CNY: Chinese Yuan; ICH: intracranial hemorrhage; AF: atrial fibrillation; NIHSS: National Institutes of Health Stroke Scale;
NA: not applicable.
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costs
The association between patient characteristics and
in-hospital costs was assessed using multivariate linearregression analysis. In patients with thromboembolism,
the direct costs were significantly related to the hos-
pital level and NIHSS scores. The equation can be
represented as: Log10 (in-hospital costs) ¼ 3.714 þ
0.127 (hospital level) þ 0.015  (NIHSS score).
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level, preadmission warfarin treatment, and prior hos-
pitalization for stroke in patients with ICH, and the
equation is: Log10 (in-hospital costs) ¼ 3.315 þ 0.377
 (hospital level)  0.458 (preadmission warfarin
treatment [yes ¼ 1; no ¼ 0]) þ 0.520  (prior hos-
pitalization for stroke [yes ¼ 1; no ¼ 0]). In patients
with major gastrointestinal bleeding, the regression
analysis showed no linear association.
Estimated economic benefits of oral anticoagulation
treatment for patients with AF
Based on the incidence of events from randomized
clinical trials for warfarin and NOACs,11e14 and the
costs data in the present study, we conducted a
simplified simulation analysis to estimate the economic
benefits of oral anticoagulation treatment for patients
with AF (Table 4).
Discussion
The results of the present study provide novel data on
in-hospital direct costs in a cohort of Chinese patients
with AF. The median in-hospital direct cost per patient
per discharge was 17,857 CNY for patients with IS and
16,589 CNY for patients with TIA. For patients with
ICH and major gastrointestinal bleeding, the costs were
27,924 CNY and 18,196 CNY, respectively. The ma-
jor drivers of direct costs were medications, which
accounted for about one-third of the total direct costs inTable 4
Simulation study on the costs imposed or saved by anticoagulation therapy.










Warfarin 1.96 0.30 0.90
Placebo 5.89 0.10 0.60







ROCKET17 Warfarin 1.42 0.70 1.37
Rivaroxaban 1.34 0.50 2.00
ICH: Intracranial hemorrhage; AF: atrial fibrillation; CNY: Chinese Yuan; R
The costs of the anticoagulant agents and international normalization ratio
a Incidence per year, based on the data in previous randomized controlled
b The larger costs minus the smaller costs per 100 patients with AF.the different groups. The direct costs were highly related
to hospital level and NIHSS scores in patients with
thromboembolism. Likewise, the predictors of total
direct costs in patients with ICH were hospital level,
preadmission warfarin treatment, and prior hospitaliza-
tion for stroke. These findings suggest the huge medical
resources consumed by AF complications in China.
In 2014, the average annual disposable income for a
Chinese household was 65,814 CNY, and the median
was 46,000 CNY.15 Quantitatively, the healthcare
expenditure of AF-related complications could be
catastrophic, given that it exceeds a 40% threshold
percentage of a household's annual expenditure
excluding expenditure for food.16,17 Insights into these
data are essential for healthcare reimbursement policy
and other policy-making decisions.
Treatment decisions for patients with AF depend
on balancing the risk of IS vs. the increased rate of
bleeding with anticoagulation. In real world clinical
practice, the economic costs should also be accounted
for.18 In previous studies, therapeutic warfarin was
associated with reduced severity of IS at presentation
and reduced disability or death at discharge in patients
with AF,19,20 which is consistent with the current study.
We also found that the direct costs for patients with
IS who had undergone warfarin treatment before
admission were less than those for patients who did not
undergo warfarin treatment.
In our simulation analysis, we found that warfarin
significantly reduces stroke, with a modest increase in









per 100 patients with AFb
59,753.30 Warfarin is associated
with 59,134.40 CNY-lower
cost than that of placebo
118,887.70
60,652.10 Dabigatran is associated
with 9921.70 CNY (110 mg)
or 8370.50 CNY (150 mg)-lower
cost than that of warfarin
50,730.40
52,281.60
69,832.30 Rivaroxaban is associated
with 4450.10 CNY-higher cost
than that of warfarin
74,282.40
CT: randomized controlled trial.
(INR) testing were not included in the analysis.
trials (RCTs).
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Compared to warfarin, dabigatran was associated with
lower direct costs while rivaroxaban was associated
with moderately higher direct costs in treating pa-
tients with AF, not accounting for the costs of the
drugs per se and those of international normalization
ratio (INR) testing.
Of note, the direct costs of in-hospital treatment of
AF-associated complications are high, compared to the
average income of the Chinese population. If improp-
erly managed, AF would impose a substantial burden
on the society. Further, the prevalence of AF is ex-
pected to rise in the future because of the aging pop-
ulation and emerging risk factors in this country 21;
thus, the importance of stroke prevention with anti-
coagulation treatment should be emphasized more in
China, given that the treatment is considerably under-
used despite some improvements in recent years.22
Data are lacking with regard to the costs that NOACs
will impose on the medical care system, despite the fact
that clinical studies have shown their efficacy in
reducing the risk of AF-related stroke, compared with
warfarin.23,24 In China, all these NOACs are not covered
by medical insurance, and the current data on in-hospital
direct costs can be applied in budget impact analysis to
assess the affordability of health technologies within
specific healthcare settings.25,26 Hence, the current data
are important for further decision-analytic models and
cost-effectiveness studies in China.27
The LOS is an independent determinant of in-
hospital direct costs.28,29 In the current study, the
median LOS for each condition was greater than
2 weeks, suggesting the need for improvement in
treatment and rehabilitation effectiveness in Chinese
hospitals. Further studies to reduce the in-hospital
direct costs are required. The current study pro-
vides information on in-hospital direct costs, which
shows that the highest proportion of in-hospital direct
costs are related to Western medicine. Nonetheless,
avoiding medical therapy without evidence for prog-
nostic benefit, such as Chinese herbs, may help
further reduce total in-hospital direct costs.
Several internal factors may also influence in-
hospital direct costs, including medical insurance sys-
tem, medical referral system, specific hospital man-
agement, and the financial status of the patients. In
China, although there are different types of medical
insurance, patients from other provinces can only
receive a portion of the reimbursement. Patients in
good financial condition typically pursue better medi-
cal care, and since the medical referral system has not
been well established, patients can directly go totertiary hospitals without referral, regardless of the
severity of the disease. These factors can also be reg-
ulatory targets for the government to reduce the eco-
nomic burden in China.
This study has several limitations. First, patients
with only TIA or IS, ICH, and major gastrointestinal
bleeding were included in this study. Second, the study
population was recruited from selected service pro-
viders located in Beijing, a relatively developed area in
China, and, thus, may not be expected to be represen-
tative of the whole country. In addition, we acknowl-
edge that in-hospital direct costs may provide limited
information, as the resource utilization of the whole
chain of care is not considered. Costs incurred after
discharge may be even higher, owing to rehabilitation,
long-term care, and impairment of work capacity or
daily activities. Although the costs were inflated to a
common price year from different calendar years, it
may not necessarily reflect the current treatment mix.
Despite these limitations, the present study still
provides detailed data on in-hospital direct costs of
AF-related thromboembolism and bleeding, and re-
veals the economic burden of AF-related complica-
tions in China. These data are essential for policy
development, service planning, and cost-effectiveness
analyses for new therapeutic agents.
Conclusion
Given the high prevalence,30 AF-related thrombo-
embolism and bleeding events impose considerable
economic burden on the Chinese society. Efforts to
improve the management of AF may confer substantial
economic benefits.
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